XML 47 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Stock-based Compensation Expense and Related Income Tax Benefit Stock-based compensation expense by statement of operations caption and the related income tax benefit were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2022202120222021
Cost of sales$38 $39 $117 $116 
Research and development expenses326 321 1,004 952 
Selling, general and administrative expenses:
Employees
1,842 1,712 5,421 5,285 
Outside directors
233 400 1,033 1,163 
Total employee and director stock-based compensation expense$2,439 $2,472 $7,575 $7,516 
Income tax benefit$397 $420 $1,265 $1,302 
Stock Option Activity
Stock option activity was as follows:    
Number of Options
(in thousands)
Weighted-Average Exercise PriceWeighted-Average Remaining Contractual Term
(in years)
Aggregate Intrinsic Value
(in thousands)
Outstanding at December 31, 2021
800 $45.55 
Granted140 33.42 
Exercised— — $— 
Forfeited/canceled/expired(74)65.54 
Outstanding at September 30, 2022 (1)
866 $41.89 3.38$34 
Vested and expected to vest at September 30, 2022 (1)
866 $41.89 3.38$34 
Exercisable at September 30, 2022 (1)
662 $42.39 2.46$34 
(1)The aggregate intrinsic value represents the total pre-tax value (the difference between our closing stock price on the last trading day of the third quarter of 2022 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had they all exercised their options on September 30, 2022. This amount will change based on the fair market value of our stock.
Assumptions Used in Valuation and Weighted Average Fair Value of Stock Option Grants
The assumptions we utilized in the Black-Scholes option pricing model and the resulting weighted average fair value of stock option grants were the following:
 Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Weighted average fair value of grants$12.38 $— $14.51 $23.97 
Risk-free interest rate2.82 %— %1.93 %0.41 %
Expected volatility48.92 %— %49.35 %48.49 %
Expected life in years5.190.004.734.62
Non-Vested Restricted Stock Award Activity
Non-vested restricted stock award activity was as follows:
Shares
(in thousands)
Weighted-Average Grant Date Fair Value
Non-vested at December 31, 2021
$310 $44.41 
Granted262 31.05 
Vested(176)41.32 
Forfeited(5)43.22 
Non-vested at September 30, 2022
$391 $36.88